Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about AGL, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
AGL holds $239.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $3.7M/quarter from operations, an estimated runway of 193.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AGL files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Steven Sell CEO & President, Director |
Insider | 943,910 | 5.62% | 2025-04-14 |
| Timothy Patrick O'Rourke CEO & President, Director |
Insider | 320,000 | 1.91% | 2026-05-07 |
| Ronald A Williams Director |
Insider | 149,141 | 0.89% | 2026-06-02 |
| Jeffrey A. Schwaneke Chief Financial Officer |
Insider | 138,031 | 0.82% | 2026-07-01 |
| Benjamin Shaker Chief Markets Officer |
Insider | 122,850 | 0.73% | 2026-04-14 |
| Denise Zamore Chief Legal Officer |
Insider | 66,075 | 0.39% | 2026-08-01 |
| Sharad Mansukani Director |
Insider | 56,242 | 0.33% | 2026-06-02 |
| Girish Venkatachaliah Chief Technology Officer |
Insider | 38,236 | 0.23% | 2026-04-14 |
| John William Wulf Director |
Insider | 16,765 | 0.10% | 2026-06-02 |
| Timothy Gertsch Chief Accounting Officer |
Insider | 14,152 | 0.08% | 2026-08-16 |
| Karen McLoughlin Director |
Insider | 8,207 | 0.05% | 2026-06-02 |
| Silvana Battaglia Director |
Insider | 7,926 | 0.05% | 2026-06-02 |
Share count 16,795,774 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AGL and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →